153 related articles for article (PubMed ID: 32422307)
1. Thymoquinone potentiates miR-16 and miR-375 expressions in hepatocellular carcinoma.
Bashir AO; El-Mesery ME; Anwer R; Eissa LA
Life Sci; 2020 Aug; 254():117794. PubMed ID: 32422307
[TBL] [Abstract][Full Text] [Related]
2. Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis.
Ashour AE; Abd-Allah AR; Korashy HM; Attia SM; Alzahrani AZ; Saquib Q; Bakheet SA; Abdel-Hamied HE; Jamal S; Rishi AK
Mol Cell Biochem; 2014 Apr; 389(1-2):85-98. PubMed ID: 24399465
[TBL] [Abstract][Full Text] [Related]
3. Thymoquinone upregulates TRAIL/TRAILR2 expression and attenuates hepatocellular carcinoma in vivo model.
Helmy SA; El-Mesery M; El-Karef A; Eissa LA; El Gayar AM
Life Sci; 2019 Sep; 233():116673. PubMed ID: 31336121
[TBL] [Abstract][Full Text] [Related]
4. Thymoquinone sensitizes human hepatocarcinoma cells to TRAIL-induced apoptosis via oxidative DNA damage.
Zhang R; Wu T; Zheng P; Liu M; Xu G; Xi M; Yu J
DNA Repair (Amst); 2021 Jul; 103():103117. PubMed ID: 33990030
[TBL] [Abstract][Full Text] [Related]
5. TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling.
Ke X; Zhao Y; Lu X; Wang Z; Liu Y; Ren M; Lu G; Zhang D; Sun Z; Xu Z; Song JH; Cheng Y; Meltzer SJ; He S
Oncotarget; 2015 Oct; 6(32):32610-21. PubMed ID: 26416455
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms.
Fatfat M; Fakhoury I; Habli Z; Mismar R; Gali-Muhtasib H
Life Sci; 2019 Sep; 232():116628. PubMed ID: 31278946
[TBL] [Abstract][Full Text] [Related]
7. Enhanced anticancer effect and reduced toxicity of doxorubicin in combination with thymoquinone released from poly-N-acetyl glucosamine nanomatrix in mice bearing solid Ehrlish carcinoma.
El-Ashmawy NE; Khedr EG; Ebeid EM; Salem ML; Zidan AA; Mosalam EM
Eur J Pharm Sci; 2017 Nov; 109():525-532. PubMed ID: 28890201
[TBL] [Abstract][Full Text] [Related]
8. Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor activity in thioacetamide-induced hepatocellular carcinoma model.
Helmy SA; El-Mesery M; El-Karef A; Eissa LA; El Gayar AM
Chem Biol Interact; 2018 Jan; 279():84-94. PubMed ID: 29133031
[TBL] [Abstract][Full Text] [Related]
9. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma.
Rashad NM; El-Shal AS; Shalaby SM; Mohamed SY
Mol Cell Biochem; 2018 Oct; 447(1-2):125-136. PubMed ID: 29455432
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Serum microRNA155 and Telomerase Expression in Hepatocellular Carcinoma.
Ezzat WM; Amr KS; Raouf HA; Elhosary YA; Hegazy AE; Fahim HH; Kamel RR
Arch Med Res; 2016 Jul; 47(5):349-355. PubMed ID: 27751368
[TBL] [Abstract][Full Text] [Related]
11. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients.
Elemeery MN; Badr AN; Mohamed MA; Ghareeb DA
World J Gastroenterol; 2017 Jun; 23(21):3864-3875. PubMed ID: 28638226
[TBL] [Abstract][Full Text] [Related]
12. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
13. Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients.
Shaheen NMH; Zayed N; Riad NM; Tamim HH; Shahin RMH; Labib DA; ELsheikh SM; Moneim RA; Yosry A; Khalifa RH
Virus Res; 2018 Aug; 255():77-84. PubMed ID: 30003924
[TBL] [Abstract][Full Text] [Related]
14. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance.
Li R; Xu T; Wang H; Wu N; Liu F; Jia X; Mi J; Lv J; Gao H
Biochem Biophys Res Commun; 2019 Nov; 519(2):358-365. PubMed ID: 31519321
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway.
Tian T; Fu X; Lu J; Ruan Z; Nan K; Yao Y; Yang Y
J Biochem Mol Toxicol; 2018 Aug; 32(8):e22167. PubMed ID: 29968951
[TBL] [Abstract][Full Text] [Related]
17. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.
Motawi TK; Shaker OG; El-Maraghy SA; Senousy MA
PLoS One; 2015; 10(9):e0137706. PubMed ID: 26352740
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone Selectively Induces Hepatocellular Carcinoma Cell Apoptosis in Synergism With Clinical Therapeutics and Dependence of p53 Status.
Jehan S; Zhong C; Li G; Zulqarnain Bakhtiar S; Li D; Sui G
Front Pharmacol; 2020; 11():555283. PubMed ID: 33041795
[TBL] [Abstract][Full Text] [Related]
19. Serum microRNA expression profiling identifies serum biomarkers for HCV-related hepatocellular carcinoma.
Li J; Jin B; Wang T; Li W; Wang Z; Zhang H; Song Y; Li N
Cancer Biomark; 2019; 26(4):501-512. PubMed ID: 31658041
[TBL] [Abstract][Full Text] [Related]
20. Loading of doxorubicin and thymoquinone with F2 gel nanofibers improves the antitumor activity and ameliorates doxorubicin-associated nephrotoxicity.
Zidan AA; El-Ashmawy NE; Khedr EG; Ebeid EM; Salem ML; Mosalam EM
Life Sci; 2018 Aug; 207():461-470. PubMed ID: 29885348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
